Evaluation of Cabazitaxel in Patients With Brain Metastasis Secondary to Breast Cancer and NSCLC

Inclusion Criteria: * Signed informed consent * Age\>18, ECOG 0-1 * Histologically confirmed 1) HER2-negative invasive breast carcinoma or 2) NSCLC * In patients with breast cancer, HER2-negative status by FISH or immunohistochemistry (score 0, or +1). * In patients with breast cancer, known estrogen and progesterone receptor status. * Evidence of measurable disease in the brain (at least 1cm) * Stable or decreasing dosage of steroids for 7 days prior to baseline MRI. * No evidence of (cortical) cognitive impairment as defined by a Mini-Mental Status Exam (MMSE) score ≥ 25/30. * No more than 4 prior lines of systemic chemotherapy in the metastatic setting * Adequate hematopoietic function defined as: * Hemoglobin ≥ 9.0g/dL * Absolute neutrophilic count ≥ 1.5 x 109L * Platelet count ≥ 100 x 109L * Adequate hepatic function defined as: * AST ≤ 2.5 x upper limit of normal (ULN) * ALT ≤ 2.5 x ULN * Total bilirubin ≤ 1.0 x ULN * Adequate renal function defined as serum creatinine ≤ 1.5 x ULN. If creatinine ranges from 1.0 - 1.5 x ULN, creatinine clearance determined by CKD-EPI formula should be calculated and only patients with clearance \>60 mL/min are eligible * Adequate contraceptive method in patients with child-bearing potential. Exclusion Criteria: * History of prior whole brain irradiation * Progressive neurological symptoms requiring immediate brain irradiation * Pregnancy or lactation * History of hypersensitivity reaction to taxanes * History of hypersensitivity to polysorbate 80 containing agents * Current or planned treatment with strong inhibitors or inducers of cytochrome P450. * Less than 3 weeks since the last treatment of chemotherapy, biological therapy, and/or immunotherapy * Leptomeningeal carcinomatosis * Contra-indication to contrast-enhanced MRI